Treatment of cancer under the impression of the COVID-19 pandemic is associated with completely new challenges. Based on several underlying factor cancer patients per se harbor an increased risk for dismal outcome of COVID. Age, malnutrition, pre-existing lung disorders and immune suppression comprise the most notable factors to be taken into account in cancer patients. As radiotherapy is one of the major pillars in oncology, there is an urgent need for recommendations on how to deal with various facets of COVID-19 in the framework of radiation oncology. The article by S. Combs et al represents the result of a consensus discussion between representatives from five large University Hospitals in Germany, Austria and Switzerland.
Featured Article: First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments
Call for papers on artificial intelligence
We are pleased to announce a new cross-journal thematic series on ‘’Artificial intelligence in Cancer imaging and diagnosis" to help bring together the latest research on the application of artificial intelligence in this field. Please click here for more information about this series.
The thematic series is now open for submission of original research and review articles. Please click here to submit your manuscript to this series.
Aims and scope
Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.
The field of radiation oncology covers the integration of radiation therapy into multimodal treatment approaches. Radiation Oncology provides an open access forum for researchers and clinicians involved in the management and treatment of cancer patients, bringing together the latest research and advances in the field. Advances in treatment technology, as well as improved understanding of the underlying biological resistance mechanisms, will further strengthen the role of radiation oncology.
Prof Claus Belka, Ludwig Maximilian University of Munich, Germany
Please click here to read the Editor's Profile.
What is trending?
Click here to see which articles published in Radiation Oncology have been shared the most in the past three months.
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Radiation Oncology is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
This special issue of Radiation Oncology – dedicated to the latest advancements in MR-guided radiotherapy – presents a collection of review and research articles highlighting the status of the field. The contributions discuss recent challenges, and present potential future directions.
Guest Edited by Dr Stefanie Corradini & Dr Maximilian Niyazi, Ludwig Maximilian University of Munich, Germany
Impact of COVID-19 on journal operations
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
We are trying our best to work through this crisis as efficiently and effectively as possible and thank you for your support and patience during these challenging times.
Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.
Research Data Support
Authors submitting to this journal can opt to use a new service that will make it easier to share research data.
The editorial team of Radiation Oncology would like to thank all of our reviewers who have contributed to the journal.
A peer-reviewed journal would not survive without the generous time and insightful comments of the reviewers, whose efforts often go unrecognized. Although final decisions are always editorial, they are greatly facilitated by the deeper technical knowledge, scientific insights, understanding of social consequences, and passion that reviewers bring to our deliberations.
Annual Journal Metrics
51 days to first decision for reviewed manuscripts only
36 days to first decision for all manuscripts
102 days from submission to acceptance
17 days from acceptance to publication
732 Altmetric mentions